Case Study: Endevica Bio accelerates peptide drug development with Quotient Sciences' Translational Pharmaceutics

Endevica Bio accelerates TCMCB07 development by 12 months with Quotient Sciences

Endevica Bio, a pharmaceutical company based in Chicago, faced the challenge of accelerating the development of TCMCB07, a novel synthetic peptide for treating cachexia. They partnered with vendor Quotient Sciences and utilized its Translational Pharmaceutics platform to address this challenge in an integrated manner.

Quotient Sciences implemented its Translational Pharmaceutics solution, which provided integrated formulation development and a Phase I clinical study program. This approach successfully accelerated the development timeline for Endevica Bio's drug candidate and saved costs in the process, with Quotient Sciences noting the platform can save as much as 12 months in development.

Endevica Bio